David Geffen School of Medicine at UCLA Health Sciences, Los Angeles, California, USA.
Department of Medicine, UCLA, Los Angeles, California, USA.
J Aerosol Med Pulm Drug Deliv. 2024 Aug;37(4):189-201. doi: 10.1089/jamp.2023.0016. Epub 2024 May 29.
Chronic obstructive pulmonary disease (COPD) is a preventable, progressive disease and the third leading cause of death worldwide. The epidemiological data of COPD from Gulf countries are very limited, as it remains underdiagnosed and underestimated. Risk factors for COPD include tobacco cigarette smoking, water pipe smoking (Shisha), exposure to air pollutants, occupational dusts, fumes, and chemicals. Inadequate treatment of COPD leads to worsening of disease. The 2024 GOLD guidelines recommend use of inhaled bronchodilators, corticosteroids, and adjunct therapies for treatment and management of COPD patients based on an individual assessment of the severity of symptoms and risk of exacerbations. This article reviews COPD pharmacotherapy in the Gulf countries and explores the role of nebulization in the management of COPD in this region. To review the COPD pharmacotherapy in the Gulf Countries, literature search was conducted using PubMed, Medline, Cochrane Systematic Reviews, and Google Scholar databases (before December 2022), using search terms such as COPD, nebulization, inhalers/inhalation, aerosols, and Gulf countries. Relevant articles from the reference list of identified studies were reviewed. Consensus statements, expert opinion, and other published review articles were included. In the Gulf countries, pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), soft mist inhalers, and nebulizers are used for drug delivery to COPD patients. pMDIs and DPIs are most prone to errors in technique and other common device handling errors. Nebulization is another mode of inhalation drug delivery, which is beneficial in certain patient populations such as the elderly and patients with cognitive impairment, motor or neuromuscular disorders, and other comorbidities. There is no major difference between Gulf countries and rest of the world in the approach to management of COPD. Nebulizers should be considered for patients who have difficulties in accessing or using MDIs and DPIs, irrespective of geographical location.
慢性阻塞性肺疾病(COPD)是一种可预防、渐进性疾病,也是全球第三大致死原因。海湾国家 COPD 的流行病学数据非常有限,因为它仍然被漏诊和低估。COPD 的危险因素包括吸烟、水烟(Shisha)、暴露于空气污染物、职业性粉尘、烟雾和化学物质。COPD 治疗不充分会导致病情恶化。2024 年 GOLD 指南建议根据症状严重程度和急性加重风险的个体评估,使用吸入性支气管扩张剂、皮质类固醇和辅助疗法来治疗和管理 COPD 患者。本文综述了海湾国家 COPD 的药物治疗,并探讨了雾化在该地区 COPD 管理中的作用。 为了综述海湾国家 COPD 的药物治疗,使用 PubMed、Medline、Cochrane 系统评价和 Google Scholar 数据库(截至 2022 年 12 月)进行文献检索,使用的检索词包括 COPD、雾化、吸入器/吸入、气雾剂和海湾国家。对确定研究的参考文献中的相关文章进行了综述。纳入了共识声明、专家意见和其他已发表的综述文章。 在海湾国家,用于 COPD 患者药物输送的装置包括压力定量吸入器(pMDIs)、干粉吸入器(DPIs)、软雾吸入器和雾化器。pMDIs 和 DPIs 最容易出现技术错误和其他常见装置处理错误。雾化是另一种吸入药物输送方式,在某些患者群体中(如老年人、认知障碍、运动或神经肌肉障碍以及其他合并症患者)有益。 海湾国家与世界其他地区在 COPD 管理方法上没有重大差异。对于无法使用 MDI 和 DPI 的患者,无论地理位置如何,都应考虑使用雾化器。